News

Reportedly, the study population will consist of patients ages 18 to 75 with symptoms of angina or myocardial ischemia. The primary endpoints are difference in Major Adverse Cardiac

Previously, Javelin had reported that the top line results for its primary endpoint were not significant. The previously disclosed top line results, based upon data captured by an

The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial

The multinational study is investigating the safety and efficacy of Pari’s L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to Pari’s drug-device combination

Taspoglutide is similar to the naturally occurring human hormone GLP-1, which plays a key role in blood glucose metabolism through a range of mechanisms. They include: improvement of

Proteome Sciences will assist Parexel early phase experts in helping biopharmaceutical companies advance biomarker discovery and qualification within clinical trials. This expanded capability allows Parexel to offer its

The Alzheimer’s disease-specific antibodies were discovered using a platform being developed by OPKO that appears to be capable of identifying such biomarkers for any disease to which the

The company claims that NuPIAO is a highly glycosylated ESA (erythropoiesis-stimulating agent), with extended half-life and increased biologic activity. The pre-clinical results showed a positive pharmacokinetic profile which

Under the five-year agreement, CRL will be Neuren’s preferred partner for clinical development. CRL presently is supporting Neuren’s phase II clinical research program with NNZ-2566, providing site monitoring,